Clinical Trial Update: Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial of sacituzumab govitecan for recurrent platinum-resistant epithelial ovarian cancer, recurrent epithelial endometrial cancer, and recurrent epithe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2026-01-21